2018
DOI: 10.1172/jci125431
|View full text |Cite
|
Sign up to set email alerts
|

Autologous graft versus myeloma: it’s not a myth

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
3
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 14 publications
0
3
0
Order By: Relevance
“…While the primary effect of auto-HCT has been attributed to cytoreductive chemotherapy, human observational studies and preclinical experimental data also implicate a degree of immune control of myeloma in autograft recipients. 45,46 In a mouse model of auto-HCT, CD8 + T cells in the donor graft conferred immune control of myeloma in an IFN-dependent-fashion. 47 Adoptive cell therapy in a syngeneic mouse model may partly depend on signals from the intestinal microbiota crossing an impaired gut barrier to augment anti-tumor immunity.…”
Section: Discussionmentioning
confidence: 99%
“…While the primary effect of auto-HCT has been attributed to cytoreductive chemotherapy, human observational studies and preclinical experimental data also implicate a degree of immune control of myeloma in autograft recipients. 45,46 In a mouse model of auto-HCT, CD8 + T cells in the donor graft conferred immune control of myeloma in an IFN-dependent-fashion. 47 Adoptive cell therapy in a syngeneic mouse model may partly depend on signals from the intestinal microbiota crossing an impaired gut barrier to augment anti-tumor immunity.…”
Section: Discussionmentioning
confidence: 99%
“…2 T TE cells, which mediate antimyeloma responses in NDMM patients, can be affected by the accumulation of noncytotoxic CD69 1 T TE cells within MILs. Tracing CD69 1 T TE cells within MILs and correlating their numbers with clinical outcome in MM patients receiving MILs as adoptive T-cell therapy33,34 could provide essential insights into role of BM-CD69 1 T TE cells in antimyeloma immunity.…”
mentioning
confidence: 99%
“…Regulatory CD4 + T cells (Treg) and cytotoxic CD8 + T cells have emerged as the dominant effectors in host myeloma control in syngeneic transplantable murine myeloma models ( 2 , 3 ) underpinning autologous graft versus myeloma as an important process in disease control ( 4 ). The dramatic success of Chimeric Antigen Receptor (CAR) T cell therapies in myeloma reinforces the vulnerability of the malignant plasma cell to T cell-mediated cytotoxicity, even though the durability of response remains an issue ( 5 , 6 ).…”
Section: Introductionmentioning
confidence: 99%